But research by Regan et al. (2012), which sought to clarify the role of CYP2D6 polymorphisms in women with breast cancer taking tamoxifen, demonstrated that risk of tumor recurrence was not associated with a specific polymorphism. This evidence concerns the gene CYP2D6 and breast carcinoma.